Patients with anti-PM/Scl-positive and idiopathic inflammatory myopathy resemble anti-synthetase syndrome

被引：0

作者：

Barbosa, Rafaella do Amaral ^{[1
]}

Shinjo, Samuel Katsuyuki ^{[1
,2
]}

机构：

[1] Univ Sao Paulo, Fac Med FMUSP, Div Rheumatol, Sao Paulo, SP, Brazil

[2] Univ Sao Paulo, Fac Med, Div Rheumatol, Ave Dr Arnaldo 455,3 Andar,Sala 3184 Cerqueira Ces, BR-01246903 Sao Paulo, SP, Brazil

来源：

ADVANCES IN RHEUMATOLOGY | 2025年 / 65卷 / 01期

关键词：

Anti-PM/Scl; Autoantibodies; Phenotypic; Systemic autoimmune myopathies; Inflammatory myopathies; Myositis; NUCLEOLAR ANTIGEN; PM-SCL; AUTOANTIBODIES; DERMATOMYOSITIS; ANTIBODIES; POLYMYOSITIS; MULTICENTER; SERIES;

D O I：

10.1186/s42358-025-00441-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Anti-PM/Scl autoantibody has been associated with an overlap between polymyositis (PM) and systemic sclerosis (SSc). However, due to limited studies, the relevance of this autoantibody in patients with idiopathic inflammatory myopathies (IIMs) without SSc was analyzed. Methods This single-center retrospective cohort study was conducted between 2004 and 2024. A total of 93 adult patients with IIMs (66 with dermatomyositis and 27 with PM - EULAR/ACR 2017) without SSc were included: 16 anti-PM/Scl(+) and 77 anti-PM/Scl(-). Patients with other types of IIMs, cancer-associated myositis, or overlap myositis, including SSc, as well as those with other myositis-specific and/or myositis-associated autoantibodies were excluded. Results The median age, sex distribution, and median follow-up duration were comparable between the anti-PM/Scl(+) and anti-PM/Scl(-) groups. There were no differences in clinical and laboratory characteristics, except for a higher frequency of lung involvement, joint involvement, "mechanics' hand," "hiker's feet," and Raynaud's phenomenon, in contrast to a lower frequency of facial rash and "V"-neck sign in patients with anti-PM/Scl(+) than in those with anti-PM/Scl(-) (all P < 0.05). Furthermore, patients with anti-PM/Scl(+) exhibited a higher frequency of disease relapse (68.8% vs. 33.8%), disease activity (50.0% vs. 24.7%), and immunosuppressant use (methotrexate or azathioprine) at the last medical evaluation (all P < 0.05). Severe infection and death rates were comparable between the groups. Conclusions Anti-PM/Scl positivity was observed in 17.2% of the sample analyzed in the present study. Patients with this autoantibody present clinical manifestations resembling anti-synthetase syndrome, with increased disease relapse and activity rates.

引用

页数：6

共 34 条

[11]

Wielosz E., Dryglewska M., Majdan M., The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis, Ann Agric Environ Med AAEM, 28, pp. 189-192, (2021)

[12]

Vancsa A., Gergely L., Ponyi A., Lakos G., Nemeth J., Szodoray P., Et al., Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients, Joint Bone Spine, 77, pp. 125-130, (2010)

[13]

Alves S.P., Silva M.G., Borges I.B.P., Shinjo S.K., Patients with pure dermatomyositis/polymyositis and anti-PM/Scl autoantibody resembling anti-synthetase syndrome, MedicalExpress, 5, pp. 1-7, (2018)

[14]

Ussavarungsi K., Nugent K., Gerke A.K., Krasowski M.D., Tuetken R.S., Lenert P.S., Interstitial lung disease associated with anti-PM-Scl antibody: a single center experience, Autoimmun Rev, 18, (2019)

[15]

Marie I., Lahaxe L., Benveniste O., Delavigne K., Adoue D., Mouthon L., Et al., Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody, Br J Dermatol, 162, pp. 337-344, (2010)

[16]

Ge Y., Shu X.M., He L., Li C., Lu X., Wang G., Interstitial lung disease is a major characteristic of patients who test positive for anti-PM/Scl antibody, Front Med, 8, (2022)

[17]

Lega J.C., Cottin V., Fabien N., Thivolet-Bejui F., Cordier J.F., Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?, J Rheumatol, 37, pp. 1000-1009, (2010)

[18]

De Lorenzo R., Pinal-Fernandez I., Huang W., Albayda J., Tiniakou E., Johnson C., Et al., Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies, Neurology, 90, pp. 2068-2076, (2018)

[19]

Kowalski E.H., Kenney H.M., Richardson C.T., Wong-type dermatomyositis with interstitial lung disease and anti-SRP and -PM/Scl antibodies treated with intravenous immunoglobulin, JAAD Case Rep, 41, pp. 26-29, (2023)

[20]

Kohara A., Yanaba K., Muro Y., Ito H., Nakagawa H., Noda K., Et al., Anti-PM/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature, Int J Rheum Dis, 20, pp. 2186-2189, (2017)

← 1 2 3 4 →